225 related articles for article (PubMed ID: 9610563)
1. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
[TBL] [Abstract][Full Text] [Related]
2. Measurement of prostate-specific membrane antigen in the serum with a new antibody.
Murphy GP; Tino WT; Holmes EH; Boynton AL; Erickson SJ; Bowes VA; Barren RJ; Tjoa BA; Misrock SL; Ragde H; Kenny GM
Prostate; 1996 Apr; 28(4):266-71. PubMed ID: 8602402
[TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific membrane antigen: current and future utility.
Gregorakis AK; Holmes EH; Murphy GP
Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
Beckett ML; Cazares LH; Vlahou A; Schellhammer PF; Wright GL
Clin Cancer Res; 1999 Dec; 5(12):4034-40. PubMed ID: 10632336
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells.
Barren RJ; Holmes EH; Boynton AL; Misrock SL; Murphy GP
Prostate; 1997 Jan; 30(1):65-8. PubMed ID: 9018338
[TBL] [Abstract][Full Text] [Related]
9. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.
Murphy GP; Elgamal AA; Su SL; Bostwick DG; Holmes EH
Cancer; 1998 Dec; 83(11):2259-69. PubMed ID: 9840525
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
11. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.
Xiao Z; Adam BL; Cazares LH; Clements MA; Davis JW; Schellhammer PF; Dalmasso EA; Wright GL
Cancer Res; 2001 Aug; 61(16):6029-33. PubMed ID: 11507047
[TBL] [Abstract][Full Text] [Related]
13. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
[TBL] [Abstract][Full Text] [Related]
14. Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay.
Xiao Z; Jiang X; Beckett ML; Wright GL
Protein Expr Purif; 2000 Jun; 19(1):12-21. PubMed ID: 10833385
[TBL] [Abstract][Full Text] [Related]
15. The clinical role of prostate-specific membrane antigen (PSMA).
Chang SS; Heston WD
Urol Oncol; 2002; 7(1):7-12. PubMed ID: 12474535
[TBL] [Abstract][Full Text] [Related]
16. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.
Chang SS; Reuter VE; Heston WD; Gaudin PB
Urology; 2001 Jun; 57(6):1179-83. PubMed ID: 11377343
[TBL] [Abstract][Full Text] [Related]
17. [Prostate specific membrane antigen (PSMA) as a role of tumor marker].
Saito S; Horiguchi Y; Murai M
Nihon Rinsho; 2002 Dec; 60 Suppl 11():145-50. PubMed ID: 12599561
[No Abstract] [Full Text] [Related]
18. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.
Gong MC; Chang SS; Sadelain M; Bander NH; Heston WD
Cancer Metastasis Rev; 1999; 18(4):483-90. PubMed ID: 10855791
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen.
Murphy GP; Greene TG; Tino WT; Boynton AL; Holmes EH
J Urol; 1998 Dec; 160(6 Pt 2):2396-401. PubMed ID: 9817391
[TBL] [Abstract][Full Text] [Related]
20. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids.
Troyer JK; Beckett ML; Wright GL
Int J Cancer; 1995 Sep; 62(5):552-8. PubMed ID: 7665226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
